- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05892926
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
March 26, 2024 updated by: AstraZeneca
A Multicenter Observational Retrospective Study of Therapeutic Approaches and Clinical Outcomes in Real Clinical Practice in Russian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma
This study is a multicenter non-interventional observational retrospective study with secondary data collection
Study Overview
Status
Recruiting
Conditions
Detailed Description
It will be multicenter study.
Planned number of study sites is about 50 oncological centers specialized on anticancer chemotherapy in various regions of Russia.
A multi-center collaborative effort will help to describe characteristics of patients with HER2-positive gastric and/or GEJ adenocarcinoma in different regions in the most comprehensive way and to capture more patients into database, not only limited to a single institution
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Arkhangelsk, Russian Federation
- Recruiting
- Research Site
-
Balashikha, Russian Federation
- Withdrawn
- Research Site
-
Belgorod, Russian Federation
- Recruiting
- Research Site
-
Chelyabinsk, Russian Federation
- Recruiting
- Research Site
-
Grozny, Russian Federation
- Withdrawn
- Research Site
-
Grozny, Russian Federation
- Recruiting
- Research Site
-
Irkutsk, Russian Federation
- Recruiting
- Research Site
-
Istra, Russian Federation
- Withdrawn
- Research Site
-
Kaluga, Russian Federation
- Recruiting
- Research Site
-
Kazan, Russian Federation
- Not yet recruiting
- Research Site
-
Kemerovo, Russian Federation
- Withdrawn
- Research Site
-
Khabarovsk, Russian Federation
- Recruiting
- Research Site
-
Khanty-Mansiysk, Russian Federation
- Recruiting
- Research Site
-
Kirov, Russian Federation
- Withdrawn
- Research Site
-
Kostroma, Russian Federation
- Recruiting
- Research Site
-
Krasnodar, Russian Federation
- Recruiting
- Research Site
-
Krasnoyarsk, Russian Federation
- Recruiting
- Research Site
-
Maykop, Russian Federation
- Recruiting
- Research Site
-
Moscow, Russian Federation
- Recruiting
- Research Site
-
Moscow, Russian Federation
- Not yet recruiting
- Research Site
-
Moscow, Russian Federation
- Withdrawn
- Research Site
-
Nalchik, Russian Federation
- Not yet recruiting
- Research Site
-
Nizhny Novgorod, Russian Federation
- Recruiting
- Research Site
-
Novokuznetsk, Russian Federation
- Withdrawn
- Research Site
-
Novosibirsk, Russian Federation
- Not yet recruiting
- Research Site
-
Novosibirsk, Russian Federation
- Withdrawn
- Research Site
-
Noyabrsk, Russian Federation
- Not yet recruiting
- Research Site
-
Omsk, Russian Federation
- Recruiting
- Research Site
-
Orenburg, Russian Federation
- Not yet recruiting
- Research Site
-
Perm, Russian Federation
- Not yet recruiting
- Research Site
-
Perm, Russian Federation
- Withdrawn
- Research Site
-
Plievo, Russian Federation
- Not yet recruiting
- Research Site
-
Rostov-on-Don, Russian Federation
- Withdrawn
- Research Site
-
Ryazan, Russian Federation
- Recruiting
- Research Site
-
Saint Petersburg, Russian Federation
- Recruiting
- Research Site
-
Saint Petersburg, Russian Federation
- Not yet recruiting
- Research Site
-
Saint Petersburg, Russian Federation
- Withdrawn
- Research Site
-
Samara, Russian Federation
- Withdrawn
- Research Site
-
Saratov, Russian Federation
- Withdrawn
- Research Site
-
Severodvinsk, Russian Federation
- Not yet recruiting
- Research Site
-
Sochi, Russian Federation
- Recruiting
- Research Site
-
Surgut, Russian Federation
- Recruiting
- Research Site
-
Syktyvkar, Russian Federation
- Withdrawn
- Research Site
-
Tomsk, Russian Federation
- Recruiting
- Research Site
-
Tver, Russian Federation
- Recruiting
- Research Site
-
Ufa, Russian Federation
- Recruiting
- Research Site
-
Ulan-Ude, Russian Federation
- Recruiting
- Research Site
-
Ulyanovsk, Russian Federation
- Withdrawn
- Research Site
-
Vladivostok, Russian Federation
- Not yet recruiting
- Research Site
-
Volgograd, Russian Federation
- Recruiting
- Research Site
-
Voronezh, Russian Federation
- Withdrawn
- Research Site
-
Yaroslavl, Russian Federation
- Recruiting
- Research Site
-
Yekaterinburg, Russian Federation
- Withdrawn
- Research Site
-
Yuzhno-Sakhalinsk, Russian Federation
- Not yet recruiting
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
300 adult patients with HER2-positive locally advanced/metastatic gastric and/or gastroesophageal junction cancer who are monitored and treated
Description
Inclusion Criteria:
- Patients with locally advanced/metastatic gastric and/or gastroesophageal junction (GEJ) adenocarcinoma, with the diagnosis established between the 1st January 2022 and the 1st January 2023.
- Patients with documented HER2+ status based on IHC score ± ISH status.
- Patients have an adequate archival tumor sample and slides suitable for reassessment HER2 status by the reference laboratory.
- Age ≥ 18 years at the time of inclusion.
- Patients provided written consent allowing for data and samples to be used in the future and this study would be covered by the consent for future use in accordance with ICH GCP, GPP (Good Pharmacoepidemiology Practices) and local law prior to inclusion in the study. If the patient is deceased, a waiver may be accepted.
Exclusion Criteria:
- Patients receiving trastuzumab deruxtecan currently or in the anamnesis.
- The participation in any randomized controlled trial within period since diagnosis (between the 1st January 2022 and the 1st January 2023) until the timepoint of data collection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe the clinical and demographic profiles of patients with HER2-positive locally advanced or metastatic gastric/GEJ adenocarcinoma in the Russian Federation
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe data on the diagnostic algorithms and therapeutic tactics in patients with HER2-positive locally advanced or metastatic gastric/GEJ adenocarcinoma in routine practice in the Russian Federation
Time Frame: 6 months
|
6 months
|
To describe data on the treatment approach in patients with HER2-positive locally advanced or metastatic gastric/GEJ adenocarcinoma in routine practice in the Russian Federation
Time Frame: 6 months
|
6 months
|
To assess the treatment outcomes of patients with HER2-positive locally advanced or metastatic gastric/GEJ adenocarcinoma in routine practice in the Russian Federation
Time Frame: 6 months
|
6 months
|
To characterize the concordance between HER2 IHC scores & ISH in local and reference laboratories
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 30, 2023
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
May 29, 2023
First Submitted That Met QC Criteria
May 29, 2023
First Posted (Actual)
June 7, 2023
Study Record Updates
Last Update Posted (Actual)
March 27, 2024
Last Update Submitted That Met QC Criteria
March 26, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D133HR00028
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma
-
Criterium, Inc.University of Colorado, Denver; NovartisTerminatedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Cholangiocarcinoma | Esophageal Adenocarcinoma | Colorectal Adenocarcinoma | Hepatocellular AdenocarcinomaUnited States
-
University of ChicagoCompletedGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Weill Medical College of Cornell UniversityMerck Sharp & Dohme LLC; Oncolys BioPharma IncNot yet recruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
Roswell Park Cancer InstituteUnited States Department of DefenseRecruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingGastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIA Esophageal... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedStage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial AdenocarcinomaUnited States